Daniel Vogel joins Genomics plc as Chief Financial Officer

Genomics plc grows its senior management team, adding international commercial and financial expertise.

5 October 2020, OXFORD, UK – Genomics plc, the health business using large-scale genetic information to transform healthcare through a prevention-first approach to health and disease risk, and to improve drug discovery, today announces that Daniel Vogel has joined the company as Chief Financial Officer.

Daniel brings to Genomics plc substantial expertise in areas ranging from strategy and corporate planning, financing, and data science. Daniel has held CFO responsibilities across Europe, Asia and Latin America, leading a wide range of teams, and has held several Board-level roles. Daniel has strong fundraising expertise across a wide range of capital structures, company stages and industry sectors.

Daniel joins Genomics plc from carwow, where he was CFO and responsible for Finance, Legal & Compliance, Data Analytics and OEM relationships. He previously was the global CFO of Compare Global Group and a Board member of several growth stage companies in the tech sector. Prior to this, he was an Executive Director at Goldman Sachs where he was part of the European Financial Institutions Practice.
Daniel holds a Masters in Banking and Finance and a Bachelors in Business Administration, from the University of St. Gallen.

Professor Sir Peter Donnelly, CEO of Genomics plc, said:
“We are delighted to welcome Daniel to Genomics as Chief Financial Officer, as part of our growing executive team. Daniel’s strong financial expertise and experience will help support the growth of Genomics at this pivotal stage of our development, as we begin to bring our products to market, establish further collaborations with healthcare partners, and build out our presence in multiple international markets and sectors.”

Daniel Vogel, CFO of Genomics plc, said:
“Genomics is in a period of rapid growth and commercialization, following on from the substantial investment in capabilities that has been made in the company over the last 5 years. I am looking forward to helping steer Genomics through this exciting phase and am thrilled to be joining a dynamic team committed to transforming population health and drug discovery.”
ABOUT GENOMICS PLC

Genomics plc is a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. Genomics plc uses large-scale genetic information to realise precision healthcare and improve drug discovery.

Genomics plc is leading the new area of genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for common diseases, well ahead of disease manifestation, allowing targeted interventions and tailored screening to prevent disease entirely, or to catch it early when outcomes remain favourable.

Genomics plc's population health management services and clinical decision support tools bring greater, earlier and more accurate understanding about individual risk for all of the common chronic diseases and cancers to doctors and their patients. The company also uses insights from genomic variation to accelerate the discovery and development of new medicines.

Backed by some of the leading investors in life sciences, the Genomics plc team is a multi-disciplinary group of scientists, engineers and deployment specialists focused on turning world-leading science into powerful and widely applied healthcare solutions, offering the chance of transforming lives around the world. Headquartered in Oxford, Genomics plc also has offices in Cambridge (UK) and Boston (US).

For additional information about Genomics plc, please visit www.genomicsplc.com.

CONTACT

Ben Atwell and Rob Winder at FTI Consulting
+44 (0)20 3720 1000
scgenomicsplc@fticonsulting.com